Ask Us
Please correct the highlighted fields below.

Alerts for Rosiglitazone

Title Date Published Source
FDA Reminds Healthcare Providers and Patients to Enroll in the Avandia-Rosiglitazone Medicines Access Program 2011-11-04
Avandia, Avandamet, and Avandaryl Soon to Be Available Only Through Avandia-Rosiglitazone Medicines Access Program 2011-05-19
FDA Update: Avandia, Avandamet and Avandaryl Labels Now Include Information About Heart-Related Risks, Patient Access Restrictions Expected Later This Year 2011-02-04
La Agencia Espanola de Medicamentos y Productos Sanitarios (AEMPS) suspende la comercializacion de Avandia, Avandamet y Avaglim 2011-01-13
All Avandia and Avandamet Product Recalled From Pharmacies and Clinics 2010-10-21
Europe-Wide Suspension of Marketing Authorisation for Rosiglitazone Products (Avandia, Avandamet) 2010-09-23
Avandia: Restricted Access Program To Be Developed 2010-09-23
Europe-Wide Review of Rosiglitazone (Avandia, Avandamet) Expected To Be Completed Soon 2010-09-08
MHRA Provides Advice About the Use of Rosiglitazone (Avandia, Avandamet) in the Treatment of Diabetes 2010-07-30
Two New Studies Suggest Diabetes Drug Avandia Increases Risk Of Heart Problems: FDA Safety Review Ongoing 2010-06-29
Rosiglitazone (Avandia, Avandamet): Update to MHRA's March 2010 Message 2010-04-16
MHRA Sends Safety Message About Avandia and Avandamet 2010-03-05
Ongoing Review of AVANDIA (ROSIGLITAZONE) and Cardiovascular Safety 2010-02-23
Thiazolidinediones Associated with Increased Risk of Fractures 2009-06-08
New additions to black box warning 2007-11-14
Some Diabetes Drugs to Strengthen Warning on Heart Failure Risk 2007-08-14

See alerts for all drugs